Literature DB >> 1992362

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.

V Kostic1, S Przedborski, E Flaster, N Sternic.   

Abstract

We evaluated whether patients with young-onset Parkinson's disease (PD) (onset between 21 and 40 years) develop levodopa-induced dyskinesias and motor response fluctuations more frequently and earlier than patients with older-onset PD (onset after 40 years) by determining the period from levodopa introduction to development of dyskinesias or fluctuations in 25 young-onset (mean age at onset, 33.54 years) and in 25 matched older-onset PD patients (mean age at onset, 55.76 years). Young-onset PD patients had significantly higher frequency for both dyskinesias and fluctuations after both 3 and 5 years of levodopa. Young-onset PD patients also developed both levodopa-induced dyskinesias and fluctuations earlier than older-onset PD patients. We suggest that the introduction of levodopa therapy in patients with young onset PD should be postponed as long as possible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992362     DOI: 10.1212/wnl.41.2_part_1.202

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

3.  Improving symptom control in early Parkinson's disease.

Authors:  Stuart H Isaacson; Robert A Hauser
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease.

Authors:  Vladana Spica; Tatjana Pekmezović; Marina Svetel; Vladimir S Kostić
Journal:  J Neurol       Date:  2012-07-22       Impact factor: 4.849

Review 5.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 6.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

7.  Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Matthew P Mount; Yi Zhang; Mandana Amini; Steve Callaghan; Jerzy Kulczycki; Zixu Mao; Ruth S Slack; Hymie Anisman; David S Park
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

8.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 9.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

Review 10.  Initiation of Parkinson's disease treatment.

Authors:  Heinz Reichmann
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.